Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Company corrects that, for the six months that ended February 28, its net asset value per share total return was negative 15%, rather than the 13% reported on Wednesday, while the company's benchmark, the Nasdaq Biotechnology Index, returned negative 23%. The correction to the return relates to dividends paid. The trust swung to a pretax loss of £48.5 million in the six months from a profit of £19.1 million a year previous. International Biotechnology Trust makes a £46.5 million loss on investments, versus a gain of £20.4 million a year before. NAV per share stands at 648.82 pence at February 28, down from 775.73p a year previous. Says the biotechnology sector has experienced a ‘significant’ period of weakness, but the company's outlook remains positive.
Current stock price: 612.00p
12-month change: down 13%
Copyright 2022 Alliance News Limited. All Rights Reserved.